HSBC downgrades Teva on uncertainty surrounding DOJ's reported generic drug investigation
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva Offers Drugs Valued at $23 Billion to End Opioid Suits - Bloomberg
Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Teva Sees Adderall Supply Delays Continuing for 2-3 Months (1)
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says | Barron's
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva Pharmaceuticals - Wikipedia
Teva Considering Cutting up to 10,000 Jobs: Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
CVS, Teva, Allergan and Endo reach $878 million deal with Florida over the opioid crisis - STAT
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva Stares Into Abyss as It Slashes Forecast, Dividends - Bloomberg
Teva CEO Steps Down After Patent Losses, Bribery Settlement; Stock Dives | Stock News & Stock Market Analysis - IBD
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva Agrees to Settle Opioid Lawsuits for as Much as $4.25 Billion - WSJ
Teva Agrees to Purchase Rimsa in $2.3 Billion Deal
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
The Difficulties of Cloning a CEO - Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva Pharmaceutical: Value at Last - WSJ
